我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

抽象的

During the COVID-19 Pandemic and Neuromyelitis Optica Therapy, Treatment Options for Patients with Neuromyelitis Optica Spectrum Disorder

Uqbah Iqbal

Neuromyelitis Optica (NMO) or device disease is a central nervous system inflammatory disorder characterized by optic neuritis and transverse myelitis episodes. In 1894, a doctor in Lyon, France, named Eugene device, described the condition. Afterward, it was thought that there was no clinical involvement beyond the optic nerve and spinal cord and that the disorder might be a variant of Acute Disseminated Encephalomyelitis (ADEM) when monophasic and a variant of classic Multiple Sclerosis (MS) when relapsing. However, NMO cases have frequently been associated with symptoms in other neurological axes.